Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assist Marguerite in the acquisition and project financing of the Brännliden wind farm.
Mandate

Vinge assist Marguerite in the acquisition and project financing of the Brännliden wind farm.

February 10, 2020 Banking and Finance M&A Energy

Vinge has adviced a fund administrated by Marguerite with the acquisition and project financing of the Brännliden wind farm. Developed by the Swedish wind power developer OX2 AB, the Brännliden wind farm will have a total effect of approximately 42 MW. NORD/LB acted as lender.

The Vinge M&A team was led by Christoffer Thalin (Energy, M&A) who was supported by Mathias Lindquist (Environmental), Philip Åberg (Land, Grid) and Niklas Törnell (M&A).

The Vinge Banking & Finance team was led by Henrik Ossborn (Banking & Finance) who was supported by Fredrik Christiansson (Banking & Finance) and Jack Bengtsson (Banking & Finance).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026